Company Profile
Ever Supreme Bio Technology provides the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. Its operations are structured into two segments: Cell Preparation Business and Operating Business segments. The company's products include umbilical cord mesenchymal stem cells, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke.
It also develops dendritic cell vaccine, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor. Its portfolio also includes chimeric antigen receptor immune cells, a chimeric antigen receptor immune cells product, and allogeneic bone-marrow stem cells, used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries.
Additionally, it develops allogeneic umbilical cord mesenchymal stem cells (UMSC01), used to treat cardiovascular diseases and strokes, as well as the sale of other health products and related businesses
Cell preparations and investment activities in biotechnology and medical industry businesses. Ever Supreme Bio Technology Co., Ltd was incorporated in 2016 and is based in Taichung, Taiwan.